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prescriptions and change in cognitive performance (i.e., inductive reasoning
and everyday problem solving), as vv'ell as how three common classes of
medication (i.e.. cardiovascular, hormone/synthetic substitutes, and central
nervous system agents) were related to cognitive performance. Data were col-
lected from 78 community-dwelling older adults (Ai = 71.14 years. SD = 5.35)
over an 18-month period. Results indicated that types of drugs were differ-
entially related to cognitive change and that the total number of prescrip-
tions was related to change in cognitive performance. Clinical and research
advantages of using specific cognitive and prescription assessments, rather
than more global measures, are discussed.
KEYWORDS. Prescription medication, cognitive change, cognitive
training
INTRODUCTION
Although older adults make up only 13% of the population in the
United States, adults aged 65 and older use approximately 30% of
prescription medications (American Association of Retired Persons
Administration on Aging, 1999). Research has found that nearly 79% of
older adults report taking at least one prescription drug, with 10% of older
adults aged 65 to 74 years reporting at least five prescriptions, and 15% of
adults aged 75 years and older reporting five or more prescriptions (Chen,
Dewey, & Avery, 2001 ). Due to the growing population of adults over the
age of 65 and the high percentage of older adults who are prescribed
medications, understanding the potential effects of these medications con-
stitutes a major health concern. One area of particular significance is the
relation between medications and cognitive functioning in later life.
Relation Between Prescription Drug Usage and Cognitive
Performance in Later Life
Improved understanding of the relation between prescriptions and
cognitive functioning is vital, given the prevalence of medication usage
and resulting cognitive side effects (Meador, 1998). coupled with norma-
tive cognitive declines (Schaie, 1996). Increasing evidence suggests that
medication-induced cognitive impairment is often mistaken for "normal"
or age-related declines, and thus is often ignored or left untreated. For
example, research examining older adult hospital patients found that
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prescription drugs were the cause of 11% to 30% of reported cases of
delirium (Francis, Martin, & Kapoor, 1990; O'Keefe & Lavan. 1999) and
2% to 12% of reported cases of dementia (Larson. Kukull, Büchner, &
Reifler, 1987; Starr & Whalley, 1994). The use of anticholinergic agents
has been strongly associated with both delirium and reversible dementia,
particulariy if an individual is taking multiple anticholinergic drugs
(Tollefson, Montague-Clouse, & Lancaster, 199Í).
In general, taking multiple prescription medications (i.e., polyphar-
macy) has been identified as a risk factor for developing drug-induced
cognitive impairment due to the cumulative effects of each drug as well as
potential drug interactions. Starr and colleagues (2004) found that greater
prescription use reported by 478 nondemented survivors of the 1932
Scottish Mental Health Survey was related to a decline in intelligence test
performance from age 11 to age 80. Factors that Increase susceptibility to
polypharmacy negative effects include gender (females are more likely to
be taking multiple medications; Chen et al., 2001), increased age
(Williams, 2002), and the presence of cognitive impairment due to other
causes (Meador, 1998; Mulsant et al., 2003).
Gaining a further understanding of the side effects of polypharmacy is
important not only for clinicians, but also for researchers, who must consider
the possible effects of multiple prescription drugs on cognitive performance
and the ensuing implications for study results and recommendations. As
much of the research on the effects of polyphannacy has used data from
institutionalized or hospitalized patients, it is important to determine how the
number of prescribed medications infiuences the cognitive performance of
relatively healthy, community-dwelling older adults. For this reason, the pre-
scription drug use of well elders was examined in the present study.
Medication Class and Varying Effects on Cognitive Performance
Examining the potential effects of medication type may also be beneficial
to further explicate the relation between prescriptions and the mainte-
nance or loss of cognitive abilities. The current study focused on cardio-
vascular drugs, hormone/synthetic substitutes, and central nervous system
agents due to the prevalence of these drugs in the older adult population
(Johnson & Moore, 1988), as well as their documented relation to cogni-
tion (see Berg & Dellasega, 1996; Gupta & Aronow, 2002).
Research suggests that cardiovascular drugs (e.g., antihypertensives) tend
to have a protective effect on cognitive ability by reducing the negative
effects of health conditions such as hypertension, which can affect visual
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memory, abstract reasoning, and attention (e.g., Andre-Petersson, Hagherg,
Janzon, & Steen, 2001). For example. Murray, Lane, and Gao (2002) found
that the use of antihypertensive, antihyperlipidemic (i.e., medications meant
to decrease triglycéride and low-density lipoprotein levels), or antiplatelet
(i.e., drugs meant to reduce or inhibit blood clotting) medications reduced the
likelihood of dementia by approximately 40% in a sample of community-
dwelling older Black adults. Longitudinal studies also support the protective
benefits of antihypertensive medications (e.g., Launer & Masaki, 1995).
Research examining the effects of hormones and other synthetic substi-
tutes on cognition has been equivocal. For example, Resnick. Metter, and
Zonderman's (1997) results support a protective role of estrogen on
women's cognitive abilities. However. Shumaker and colleagues (2003)
found that older women taking estrogen and progestin were actually at a
higher risk for developing dementia. The effect of hormones and synthetic
substitutes on the cognitive performance of males is also unclear.
Janowsky, Chavez, and Orwoll (2000) found that older males taking test-
osterone supplements scored higher on working memory tasks compared
with older males taking a placebo. However, as Asthana (2003) points out,
the equivocal results of these studies may be due to the employment of cog-
nitive measures that are too global, and the effects of prescribed medica-
tions may be more salient in specific cognitive domains (e.g., Duka, Tasker,
& McGowan, 2000). Both points relate to the current study.
The third class of drug examined in the present study was central ner-
vous system (CNS) agents, which included such medications as hypnotics
and sedatives, analgesics, and psychotropic agents. Berg and Dellasega
(1996) found that the use of psychotropic drugs had a significant and
cumulative negative effect on verbal ability, spatial relations, and picture
recognition. In addition, McShane and colleagues (1997) found that
patients with dementia who were taking psychotropic drugs displayed a
decrease in cognitive pertbrmance twice that of a sample not taking psy-
chotropic medication. Likewise, hypnotics such as benzodiazepines, as
well as anticonvuisants have been related to decreased cognitive function-
ing in older adults (Moore & O'Keeffe, 1999).
Study Rationale
The present study sought to further the understanding of the relation
between change in cognition and change in medications in a sample of
community-dwelling older adults. This study u.sed specific cognitive
treasures (i.e., inductive reasoning and everyday problem solving) to
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more finely examine the potential association between medication and
cognition in terms of both the number of prescriptions older adults
report and the specific medication classes. Inclusion of an everyday
problem-solving measure addressed a dimension of cognition that
has not been previously examined in relation to medications in a
population of community-dwelling older adults. This is important, as
everyday problem-solving measures are likely more predictive of func-
tional ability than are basic cognitive measures (Allaire & Marsiske,
2002).
Two methodological advantages of this study should also be noted.
First, because of the longitudinal nature of this study, the relation between
change in the number of prescriptions (and specific prescription classes)
and change in cognitive performance can be assessed. Second, this study
used the medication "brown bag" method to collect data on the number
and type of prescriptions, which enables the researcher to check the infor-
mation for each medication as recorded on tbe actual medication bottle
(e.g., Caskie. Willis, Schaie, & Zanjani, 2006). While this method does
not necessarily mean that participants are actually taking the medication
properly, it does present the advantage that researchers do not need to rely
solely on self-reported data.
METHOD
The older adults in this study were recruited to participate in a cogni-
tive training protocol designed to improve inductive reasoning and to
compare the effects of individual versus collaborative training with a
spouse. The training consisted of 10 sessions, the majority of which were
completed by participants in their own home. Current study procedures
related to random group assignment, administration of training materials,
and follow-up assessments correspond to prior cognitive training research
(Ball et al., 2002; Willis & Schaie, 1994; more detailed information is
available in Saczynski, Margrett, & Willis, 2004, and Margrett & Willis,
2006). It is important to note, however, that study advertisements and
descriptions did not target persons with cognitive impairments (e.g., this
was not advertised as a program to treat or enhance cognitive perfor-
mance) and such individuals were excluded from participation during
screening. Use of this particular sample allowed us to examine the
relative importance of prescribed medication within a cognitive training
paradigm.
102 CLINICAL GERONTOLOGIST
Participants
Participants were part of a convenience sample recruited through local
media and community organizations. The sample included 106 older
adults who were screened prior to study enrollment to ensure that the
participants were community-dwelling and reported no limitations in self-
care activities. Out of this original sample. 78 participants (40 females
and 38 males) had complete medication data at baseline and the 18-month
follow-up. Analyses found no significant differences in age, education, or
number of medications at baseline between the participants that were
included in the present analyses and those who were not included.
The mean age ofthe final sample (A'^ 78) at baseline was 71.14 years
(SD = 5.35; range = 61 to 83 years). The average educational level was
16.09 years (So = 3.05; range = 12 to 22 years) with 76% of participants
reporting an educational level of more than twelve years. The median
yearly income was $47,644 (range = $18,000 to $50,000+). All partici-
pants resided in rural central Pennsylvania and were White.
Procedure
Due to the nature of the larger training study, older married couples
were recruited and screened for eligibility during a brief phone interview
(for a similar study, see Margrett & Marsiske, 2(X)2). The screening criteria
were; (a) 60 years of age or older; (b) no self-reported limitations in activ-
ities of daily living (i.e., bathing, dressing, personal hygiene; Katz, Ford,
Moskowitz, Jackson, & Jaffee, 1963); and (c) a minimal marital duration
of at least 15 years (Carstensen, Levenson, & Gottman, 1995). Although
couples were originally recruited for the larger study, the current analysis
includes data from individuals who had complete data (i.e., both partners
did not have to have complete data for one spouse to be included in the
current analyses). At the study start, both spouses within a couple were
randomly assigned to one of three training conditions and those respon-
dents included in the current analyses were assigned as following; (1)
Individual Training group (n = 22 individuals), (2) Collaborative Training
group (n = 26 individuals), and (3) Questionnaire Only (control) group
(« = 30 individuals).
All participants signed an informed consent form and were treated in
accordance to the ethical guidelines set forth by the American Psychological
Association (2002). Couples received compensation for parking and a
small honorarium based on their hours of effort (i.e., $40 for the two
training groups and $20 for the nontraining group).
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Pretest and Posttest Assessments
The analyses reported in the current study focus on the baseline and an
18-month follow-up assessment. The first assessment occasion was a
3-hour group baseline assessment conducted immediately prior to cognitive
training. The second assessment was a delayed posttest that was con-
ducted 18 months after the baseline session. During both assessments,
participants completed the Letter Series Test (Blieszner, Willis, & Baltes,
1981), the Everyday Problems Test (EPT; Willis & Marsiske, 1997), and
a demographic measure. Participants in all three treatment groups were
assessed under the same conditions—at a community or university setting,
in small groups with a trained proctor. Spouses participated in the pretest
and post-test assessments together. Each group testing session contained a
combination of 2 to 3 couples from each ofthe three treatment conditions.
Testing was arranged in this manner in order to prevent testing of only
one treatment condition at a time which could conceivably affect testing
outcome (e.g., tester bias, altered group dynamics). The length of time
between pre- and posttests was consistent across the three groups.
Reasoning Training Protocol
The training protocol used in the current study was based on prior work
by Willis (e.g.. Ball et al., 2002; Willis & Schaie, 1994). Information was
presented in workbook form, and the training consisted of ten sessions
designed to introduce and reinforce inductive reasoning strategies helpful
in determining pattems needed to navigate daily life (e.g., compiling a
medication chart). The training materials utilized both basic series (e.g.,
letter, words) as well as stimuli common to everyday life (e.g., transporta-
tion schedule). The training was expected to improve performance on
inductive reasoning measures.
Training consisted of 10 sessions that were completed over a four to 5-
week period. Sessions consisted of the introduction of five strategies to
improve inductive reasoning performance (e.g., undedine repeated elements,
insert a slash between pattem repetitions) and opportunities to practice
inductive reasoning on elementary items (e.g., letter and word series) and
items of a practical nature (e.g., transportation schedule). After the initial
session, training occurred in participants' homes. Participants in the Individ-
ual group completed all materials individually, without assistance from their
spou.se. In contrast, trainees in the Collaborative group completed all ses-
sions with their spouse. Participants assigned to the Control group completed
the same pre/posttests as the training groups, but did not receive training.
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Measures
Letter Series Test
To assess inductive reasoning ability, participants completed the Letter
Series Test (Blie.szner et al., 1981). This 20-item timed measure gauged
respondents' ability to identify the pattem in a series of letters and to
generate the next letter in each series. This measure displays good intemal
reliability (a = 0.91 ; Blieszner et al.) and test-retest reliability (r = 0.84;
Schaie, Dutta, & Willis, 1991). In terms of validity, this measure was
related to everyday problem solving (Comelius & Caspi, 1987) and other
tests of inductive reasoning (e.g., word series; Willis & Schaie, 1986).
Change scores were calculated by subtracting the number of correct items
at baseline from the number of correct items at the 18-month posttest;
thus, positive change scores indicated an increase in performance. Results
indicated a significant increase in pertbrmance at Time 2 (range = -4 to 8;
see Table 1), with the training conditions improving significantly more
than the control condition. Thus, condition was entered in all ofthe analyses.
TABLE 1. Sample descriptive information (W= 78)
Variable
Health-related Information
Seif-rated physical heaith
Hospitai visits (days within
iast six months)
Average number of
prescriptions
Cognitive Performance
Everyday Problems Test
Letter Series Test
Reported Prescriptions within
Cardiovascular only
Hormone/Synthetic only
Central nervous system
agent only
Combination of categories
No prescriptions from
three study categories
Baseline
Mean (SD)
2.48 (0.77)
0.47(1.37)
2.73 (2.27)
31.39(6.42)
8.38(3.21)
Range
1-5
0-10
0-8
•1
11-41
1-16
n i-o
Drug Category
16
10
3
28
21
20.5%
12.8%
3.8%
35.9%
26.9%
18-month Posttest
Mean (SD)
2.65(1.10)
1.90(0.31)
3.40 (2.24)
31.29(6.74)
9.69 (3.68)
n
16
10
3
28
21
Range
1-6
1-2
0-8
11-42
1-20
20.5%
12.8%
3.8%
35.9%
26.9%
Statistical
Tests
f
-1.60
-8.38
-3.06
-0.24
4.63
P
0.11
<0.01
0.03
0.80
<0.01
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Everyday Problems Test
The Everyday Problems Test (EPT) (Willis & Marsiske. 1997) was
designed to assess older adults' ability to solve problems in seven critical
everyday domains (i.e.. Instrumental Activities of Daily Living; Lawton
& Brody. 1969), such as health and financial management. A 42-item
open-ended version of the test was used. Participants were presented with a
stimulus (e.g., a Medicare chart) and asked to solve age-relevant problems
(e.g., calculating the Medicare portion of a hospital stay). This measure
displayed good intemal consistency in past research (alphas ranging from
0.62 to 0.74 for the subscales and 0.94 for the entire scale) and high test-
retest stability (.91 for entire scale; Marsiske & Willis, 1995). In addition,
Whitfield, Baker-Thomas, Hey ward. Gatto, and Williams (1999) found
the EPT to be related to measures of fluid intelligence (e.g., inductive
reasoning). Change scores were calculated by subtracting the number of
correct items at the 18-month post-test from the number correct at base-
line. The average EPT change from Time 1 to Time 2 was not significant
(range = -9 to 8; see Table 1 ). Although there were not overall changes in
means on the EPT between Time 1 and Time 2, it was decided that pre-
dictors of change were still important, given the variability in perfor-
mance and the relation between basic cognitive measures and everyday
cognitive measures (Marsiske & Willis, 1995).
Prescription Medication Data
Prescription data were collected using the "brown bag" method as used
in the Seattle Longitudinal Study (.see Caskie,Willis, Schaie, & Zanjani,
2006), which entailed older adults bringing their medications with them to
the testing session (Caskie,Willis, Schaie, & Zanjani, 2(X)6). Information
including the name ofthe medication, dosage, and most recent refill date
was recorded by the test administer. Following testing, prescriptions were
then coded by trained research assistants supervised by the first and
second authors. Prescriptions were double-coded, and if a discrepancy
was found, the coders referred to the raw data to determine the correct
classification based on the reported indication when available. This
classification was then checked by the first and/or second authors. Dis-
crepancies between coders were minimal. Each medication received an
American Hospital Formulary Service (AHFS, 2004) code, which classi-
fied medications according to increasingly specific categories (e.g., Level
One: cardiovascular; Level Two: beta-blocker). The present study used
the major drug classification specified at level one. While using this broad
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classification scheme does not provide information regarding the effects
of specific prescription medications, this strategy does provide information
regarding the effects of specific categories of medications on specific
assessments of cognitive performance. These results can then be used to
inform future research on the effects of more specific classes of medications.
For the prescription drug data, an initial baseline was collected imme-
diately after cognitive training. At this titne, participants were asked to
report any medication changes since the study inception 7 to 8 weeks
prior. The majority of participants (88.5%) reported no changes in
medication usage during that interval, with an additional 7.5% reporting
adding one medication, 1.25% reporting dropping a medication, and
2.75% reporting an increase of two medications or more. The number of
medications reported at the immediate follow-up was adjusted according
to participants' reports. This resulted in a baseline indicator (e.g., if four
medications were reported at the immediate foHow-up and one medication
was added in the period between baseline and the immediate follow-up,
the adjusted baseline score was three medications). Eighteen-month
change scores were calculated by subtracting the adjusted number of total
medications at baseline from the number of prescriptions recorded at the
18-month posttest (see Table 1). Overall, participants reported taking
more medications at Time 2 compared to Time 1, with the change in the
number of prescriptions ranging from -4 to 6. Although the difference
between Time 1 and Time 2 data was statistically significant, the practical
significance of this slight increase likely depends on the type of medication(s)
being added. This suggests that number of drugs, per se, may not possess
adequate specificity when examining the relation between prescription
medications and cognition. Thus, number of medications and medication
class was examined in the present study.
Health Information
As part of a pre-session homework package, participants completed a
paper-and-pencil demographic measure that included items assessing
self-reported ratings of physical health and number of hospital visits
within the past 6 months. Current physical health compared to health at
20 years of age was indicated on a scale from 1 {Very Good) to 6 {Very
Poor). As shown in Table 1, analyses indicated that the number of hospital
visits reported for the previous 6 months increased from Time 1 to Time
2, but self-rated physical health did not change from Time 1 to Time 2.
There were no statistically significant differences between the training
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and control conditions on the number of hospital visits, self-rated health,
scores on the EPT, or scores on the Letter Series Test at Time I or at
Time 2.
RESULTS
The following analyses focused on the predictive utility of medication
usage in relation to change in performance on the Letter Series Test
(Blieszner et al., 1981) and Everyday Problems Test (Willis & Marsiske,
1997) over an 18-month interval. Both the type of medications and the
change in the number of medications were examined as predictors. Prior
to these analyses, general descriptive statistics regarding group differ-
ences and overall prescription usage are reported (i.e., total number of
prescriptions and percentage reporting prescriptions from the three most
common drug classes: CNS agents, cardiovascular drugs, and hormone/
synthetic substitutes). Initial analyses identified a potential outlier who
reported a large change in the number of hospital visits from Time 1 to
Time 2; however, the pattem of results remained consistent regardless of
whether this outlier were included or not. Thus, the following results are
based on data from the entire sample {N = 78).
Descriptive Statistics
Overall, 80% of the sample reported taking at least one prescription
drug. Ofthe participants who reported a prescription from the categories
of interest in this study, results indicated that approximately 28% reported
taking only cardiovascular drugs, 5% reported taking only CNS agents,
18%' reported taking only hormone/synthetic substitutes, and 49%
reported prescriptions from two or more of these categories (see Table 2
for detailed description of particular types of drugs under each main
AHFS category). Additionally, 25% of participants reported a combina-
tion of prescriptions from these three drug categories and prescriptions
that did not fall under the three studied categories (e.g., a cardiovascular
drug and an anti-infective agent).
An examination of group differences in the use of the specific classes
of prescription medications at Time 1 indicated that females were more
likely to report taking hormone/synthetic substitutes (28%) compared
with males (9%), x^ (1. A' = 78) = 9.84, /? < 0.01, and that females were
more likely to report taking CNS agents (25%) compared to males (10%),
108 CLÍNICA L GERONTOLOGIST
TABLE 2. Number and type of prescription medications included under
primary AHFS categories
Drug Type
Cardiovascular
Cardiac drugs
Antilipemic agents
Hypotensive agents
Vasodilating agents
Alpha adrenergic blocker
Beta adrenergic blockers
Calcium-channel blockers
Renin-angiotensin-aldosterone system inhibitors
Central Nervous System Agents
Analgesics and antipyretics
Anticonvuisants
Psychotherapeutic agents
Anxiolytics. sedatives, and hypnotics
Hormones & Synthetic Substitutes
Adrenals
Estrogens & antiestrogens
Antidiabetic agents • '
Parathyroid '
Progestins
Other corpus luteum hormones
Thyroid and antithyroid agents
Time
N
75
2
22
35
6
0
10
0
0
24
8
2
11
3
38
0
11
5
0
5
5
12
1
%
2.7
29.3
46.7
8.0
0.0
13.3
0.0
0.0
37.5
4.2
37.5
8.3
0.0
28.9
13.2
0.0
13.2
13.2
31,6
Time
N
86
1
23
33
2
5
11
3
8
26
10
2
10
4
35
4
10
3
2
3
3
10
2
%
1.2
26.7
38.4
2.3
5,8
12.8
3.5
9.3
38.5
7.7
30.8
15.4
11.4
28.6
8.6
5.7
8.6
8.6
28.6
Note. The listed drug types reflect only those that were reported by participants and are not
a comprehensive list of all types of prescriptions under each category (note that participants
may have reported multiple prescriptions in any given category).
X^  (1, /V = 78) = 4.53, p < 0.05. Males (40%) and females (32%) did not
differ significantly in the likelihood of taking a cardiovascular drug. With
regard to the treatment groups, there were no significant differences in
terms of age, number of medications, types of medications, number of
hospital visits, or self-rated physical health. Possible baseline differences
between participants who reported a prescription from at least one of the
studied categories and those who did not were explored using a series of
i-tests. Results indicated that these groups did not differ in terms of
performance on the cognitive tasks, number of hospital visits, age, or self-
rated physical health.
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Change in Number of Medications and Change in Cognitive
Performance
Hierarchical multiple regression analysis was conducted to examine
the relation between change in number of prescription medications and
change in cognitive performance (i.e.. Letter Series Test and Everyday
Problems Test). Several additional predictor variables hypothesized to be
related to cognitive performance were entered into the model. The four
regression steps included: (a) demographics (age, sex, educational
attainment), (b) training condition and baseline performance on the
respective cognitive task, (c) health indicators (change in self-rated
health and change in hospital visits from baseline to 18-month post-test),
and (d) change in number of reported prescription medications ( 18-month
post-test - baseline).
First, a hierarchical multiple regression was performed to examine the
relation hetween the change in the number of medications reported and
the change in performance on the Letter Series Test (Blieszner et al.,
1981). As shown in Table 3, results indicated that the demographic
variables did not significantly contribute to the prediction of change in
performance. The addition of step two (training condition and baseline
performance) did significantly increase the amount of explained variance.
The addition of step three (health indicators) did not significantly increase
the amount of explained variance. Inclusion of step four (change in num-
ber of medications) did significantly increase the amount of explained
variance. The overall model accounted for a significant portion of the
variance in change in performance on the Letter Series measure (R^ = 0.21,
p < 0.05).
Results of the hierarchical multiple regression analysis examining
change in performance on the EPT (Willis & Marsiske, 1997) were
similar to the previous analysis (see Table 3). Once again, steps one
(demographics) and three (health indicators) did not explain a significant
amount of variance in change in EPT perfomiance. However, the addition
of steps 2 (training condition and baseline performance) and step 4
(change in number of medications) significantly increased the amount of
explained variance. The overall model accounted for 21.5% ofthe vari-
ance in performance on the EPT {p < 0.05).
Results from these regression analyses suggest that an increase in the
number of reported prescriptions was positively related to change scores
on both the inductive reasoning task and the everyday problem-solving
task. Age, baseline EPT scores, change in hospital visits, and change in
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TABLE 3. Results of hierarchical regression analyses examining total
number of reported prescriptions
Predictor
Stepi
Age
Education ., .
Sex
Step 2
Training condition
Baseline cognitive score
Step 3
Change In hospital visits
Change in self-rated
physical health
Step 4
Change in total number
ot prescriptions
Totai R^
Totai F
Letter Series Test
Afí^ B
0.02
-0.02
0.11
0.43
0.10*
0.60
-0.17
0.02
0.25
-0.01
«.
0.07**
0.34
SEB
0.06
0.10
0.60
0.34
0.10
0.19
0.30
0.14
0.21*
(8. 71) = 2.;22. p<
ß
-0.06
0.13
0.09
0.19
-0.22
0.15
-0.03
0.26*
0.05
Everyday Problems Test
AR"
0.02
0.08*
0.06
0.05"
(8.
S
-0.16
0.11
-0.18
0.29
-0.16
-0.60
0.01
0.44
SEB
0.07
0.16
0.90
0.50
0.07
0.28
0.46
0.21
0.21"
71)= 2.35. p <
ß
-0.25*
0.09
-0.02
0.06
-0.27*
-0.24*
0.01
0.23"
0.05
Note. *p < 0.05, " p < 0.01.
total number of prescriptions were predictive of change in everyday
problem-solving performance.
Category of Medication and Change in Cognitive Performance
The next series of analyses examined the relations between the
reported use of cardiovascular drugs, hormone/synthetic substitutes, and
CNS agents at baseline and 18-month change in performance on the two
cognitive measures. A series of 2 (Drug: Taking or Not Taking Medication) x
2 (Sex: Male, Female) x 3 (Training Condition: Control, Individual, Col-
laborative) analyses of covariance (ANCOVA) tests was performed
(covarying education and age) for each cognitive task and prescription
category (see Table 4).
Prior to performing these analyses, we examined the stability of pre-
scription use between the baseline assessment occasion and the 18-month
post-test in terms of whether participants were taking or not taking drugs
within the 3 categories of interest (e.g., taking a cardiovascular drug at
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TABLE 4. Analyses examining the relation between change in number
' . of prescriptions and change on cognitive measures
Source
Cardiovascular Drugs
Age (covariate)
Education {covariate)
Cardiovascular Drug (CD)
Training Condition (TC)
Sex(S)
CDXTC
C D X S
T C X S
CD X TC X S
Central Nervous System Agents
Age (covariate)
Education (covariate)
Central Nervous System Agent
(CNS)
Training Condition (TC)
Sex(S)
CNS X TC
CNS X S
T C X S
CNS X TC X S
Hormone/Synthetic Substitutes
Age (covariate)
Education (covariate)
Hormone/Synthetic Substitutes
(HSS)
Training Condition (TC)
Sex (S)
HSS X TC
HSSXS
T C X S
HSS X TC X S
di
1
1
1
2
1
2
1
2
2
1
1
1
2
1
2
1
2
2
1
1
1
2
1
2
1
2
2
Letter Series Test
MS
0.01
0.01
1.47
16.56
5.09
4.41
0.72
3.16
1.62
1.03
0.35
2.09
7.95
6.45
14.24
8.67
4.29
10.34
5.13
6.25
23.45
20.91
30.62
10.61
42.38
7.29
15.44
F
0.01
0.02
0.23
2.42
0.79
0.69
0.11
0.49
0.25
0,19
0.06
0.37
1.42
1.15
2.54
1.55
0.77
1.85
1.21
1.43
5.35*
4.77"
6.98*
2.42
9.67"
1.66
3.52'
Everyday Problems Test
df
1
1
1
2
1
2
1
2
2
1
1
1
2
1
2
1
2
2
1
1
1
2
1
2
1
2
2
MS
15.82
4.22
67.64
3.57
4.97
29.60
28.47
4.47
6.19
28.74
2.59
0.02
5.98
22.38
6.05
68.46
0.30
3.53
24.38
0.02
1.06
0.16
2.14
8.80
17.90
9.55
14.82
F
0.62
0.31
4.97*
0.26
0.37
2.17
2.09
0.33
0.45
1.99
0.18
0.01
0.42
1.56
0.42
4.75*
0.02
0.62
1.64
0.01
0.07
0.01
0.14
0.59
1.20
0.64
1.00
Note, 'p < 0.05.
Time I compared with if the participant was taking a cardiovascular drug
at Time 2). All of these correlations were extremely stable, with correla-
tions approaching (p = I. Given this stability, participants' Time 1 data
were used in the analyses. It should be noted that the following analyses
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address how the stable use of particular classes of medications is related
to cognitive performance, which is in contrast to the previous analyses
that examined change in total number of medications.
Cardiovascular Drugs
The results ofthe ANCOVA examining the effect of taking at least one
cardiovascular drug on the change in the performance on the Letter Series
Test (Blieszner et al.., 1981) revealed no differences between participants
who were taking a cardiovascular drug {M = 1.17, 5£) = 2.22) compared
to those who did not (A/ = 1.43, SD = 2.72). In addition, the effects of train-
ing condition and sex were not significant.
In contrast, there was a significant effect of taking a cardiovascular
drug when examining the change in scores on the EPT (Willis &
Marsiske, 1997). Specifically, participants taking a cardiovascular drug
also displayed a mean increase in scores from the pretest to the ]8~month
post-test {M = 0.94, SD = 3.41), while those not taking a cardiovascular
drug displayed a mean decrease in EPT scores (M = -1.00, SD = 3.79).
The effects of sex and training condition were not significant.
Central Nervous System Agents . . . .
Analyses examining the change in Letter Series Test scores revealed
no significant effects of taking CNS agents, training condition, or sex on
inductive reasoning performance, covarying for age and education.
Regarding EPT change scores, ANCOVA analyses revealed no signifi-
cant main effects for taking a CNS agent, training condition, or sex on
cognitive performance. However, a significant interaction was found
between sex and use of CNS agents. Simple effects analyses revealed that
females taking CNS agents (mean change = -2.08, SD = 3.96) performed
significantly worse compared with females who did not take CNS agents
(mean change = 0.89, SD = 4.16), F{ 1, 67) = 4.05, p < 0.05. There was no
significant simple drug effect for males, p > 0.05.
Hormone/Synthetic Substitutes
Due to the potential differences between hormones and other synthetic
substitutions, separate analyses were performed for participants pre-
scribed hormones and those prescribed other synthetic medications. The
pattern of results for those reporting prescription hormone use was identi-
cal to the results from the entire subsample who reported taking any drug
from this category (n = 29). However, no significant findings were
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evident for the participants who reported taking only a nonhormonal drug
from this category (n = 5), which was likely due to the test being
extremely underpowered. The results that are reported reflect participants
taking any drug from this category.
The results of the ANCOVA revealed a significant effect of taking
hormone/synthetic substitutes, as well as significant effect of training condi-
tion and sex on change in Letter Series Test scores. However, these main
effects were qualified by significant Drug x Sex x Training Condition inter-
action. Simple interaction analyses indicated that the simple interaction
between taking hormones and training condition was significant for females,
f(2. 66) = 12.03. /? < 0.01. but not for males, p > 0.05. The simple simple
effects analyses revealed a training condition effect for female participants
taking a hormone/synthetic substitute, F(2, 66) = 4.09, p < 0.05, and for
those that did not take this type of drug, f{2,66) = 8.83,p < 0.05. See Figure 1
for the results of the simple comparison analyses. With regard to males,
simple effects analyses revealed a simple effect for training condition, F{2.,
66) = 4.04, p < 0.05. and for whether the participants were taking a
hormone/synthetic substitute or not, F{ 1,66) = 9.44, p < 0.01 (see Figure 1 ).
Regarding the change in EPT scores, no significant effects were found
for sex, condition, or taking a hormone/synthetic substitute.
In summary, the number of prescriptions and drug category was related
to change in scores on an inductive-reasoning task and an everyday
problem-solving task. However, these relations differed across the three
medication categories, indicating that the overall number of drugs people
take may not be sensitive enough to fully understand the relation between
prescription medication and cognitive performance. It should also be
noted that the pattern of results did not change when total number of pre-
scriptions was entered as a covariate, suggesting that the results are not
merely an issue of polypharmacy. • ^
DISCUSSION
The primary purpose of this research was to examine how both the num-
ber and types of prescription medications older adults take were related to
the change in performance on two specific cognitive tasks (everyday prob-
lem solving and inductive reasoning). In general, the results indicated that
change in cognitive perlbrmance was related to both the number of pre-
scriptions and specific drug classification, and differed by the cognitive
measure being analyzed. Each of these findings is discussed in turn.
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FIGURE 1. Simple Interactions of Drug x Training Condition x Sex,
Broken Down by Sex. For males, the simple interaction was not
significant. The simple main effects of Drug and Training were both
significant, with fo!iow-up tests indicating that the participants in the
individual condition scored higher than the control group and that males
taking hormone/synthetic drugs scored lower than those who did not. For
females, the simpie-simple interaction was significant, with simple-simple
effect analyses indicating a Training Condition effect in femaies who were
and were not taking synthetic drugs. Note that bars with the same letters
above them were significantly different (e.g., within females not taking this
type of drug, the control group significantly differed from the coilaborative
training condition). •^'
• Control
• Individual
D Collaborative
Hormone/Synthetic Drugs: Males
? -2
(0
6 -3
_4 J
• Control c
• Individual -,.
• Coilaborative
Hormone/Synthetic Drug: Females
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Somewhat surprisingly, an increase in the total number of reported
medications was positively related to an increase in scores on both cogni-
tive measures over the 18-month follow-up period. This finding is incon-
sistent with the extant literature which generally reports that greater
medication use is related to poorer cognitive performance (e.g., Meador,
1998; Starr et al., 2004). However, much ofthe past research has relied on
data collected from institutionalized or ill older adults who are at higher
risk for polypharmacy, whereas the data in this study were provided by
healthy, well educated, community-dwelling older adults. Thus, rather
than the number of medications representing health, per se, the number of
prescriptions may be a proxy for such protective factors as access to
health care (Stuart & Grana, 1998), attitude toward health care, or
increased awareness of health-related risk factors that may have deleteri-
ous effects on cognition (e.g., hypertension). Additionally, there may be a
threshold, which the participants in this study did not reach, at which
increased prescription use may be detrimental to cognitive performance.
Next, we examined the relation between specific prescription category
and change in two measures of cognitive performance. Consistent with
past literature, a protective effect of cardiovascular drugs was found, but
only for performance on the everyday cognition measure. In the present
sample, the use of cardiovascular drugs offered some protection against a
decline on an executive functioning task assessing everyday functional
ability (Allaire & Marsiske, 2002), but not on a measure that assessed a
more basic cognitive ability, namely inductive reasoning.
The results from the hormone/synthetic substitutes analyses indicated
varying effects depending on the cognitive measure. The use of hormone/
synthetic substitutes was not related to change in performance on more
complex everyday problem-solving tasks. However, with regard to the
inductive reasoning measure, the three-way interaction between sex,
training condition, and whether or not participants were taking hormone/
synthetic substitutes indicated that taking hormone/synthetic substitutes
had a negative effect for men regardless of training condition. In contrast,
for females taking hormone/synthetic substitutes the direction of the
effect was different depending on the training group to which they were
assigned. The finding that females in the control group benefited from
taking hormone/synthetic substitutes is consistent with the literature sug-
gesting a protective roie of such drugs as estrogen (e.g., Resnick et al.,
1997). However, additional research is needed to disentangle the interaction
between the training condition and taking hormone/synthetic substitutes.
Within a larger sample reporting more varied prescriptions, analyses
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examining more specific subclasses of hormone/synthetic substitutes
could further clarify this relation. Caution must be taken in interpreting
these results, however, due to the relatively small number of males taking
hormone/synthetic substitutes and the lack of knowledge regarding the
reasons that the participants were taking a drug from this category, which
may be quite different for males and females.
Finally, the results for CNS agents suggested that these medications
can have different effects depending on the measure of cognitive perfor-
mance being used. Consistent with past research (Francis et al., 1990),
taking CNS agents had a negative effect on cognitive performance, but
this relation was only found for females. However, it should be noted that
this finding may be due to the relatively low number of males reporting
taking a CNS agent (7.5%) and the resulting loss of power. These results
are further qualified by the broad range of medications that fall under this
category, some of which have different effects on cognitive performance.
However, this does not necessarily discount the finding that CNS agents
have a differential infiuence on specific components of cognitive perfor-
mance. Future research with a larger sample could clarify the relations
between specific CNS agents and induction reasoning and everyday
problem solving.
Due to the differential findings across the two cognitive measures, the
results of this study support the use of more domain-specific cognitive
measures when examining potential effects of prescription medications.
In addition, when examining the relation between prescription drug usage
and cognitive performance, category-specific classifications appear to be
more sensitive measures of prescription use compared to sole reliance on
the total number of medications.
Considerations and Future Directions
Several issues should be considered when interpreting the findings in
this study. First, it is possible that cognitive performance may have been
infiuenced by either the drug itself or the alleviation of symptoms the
drug is designed to treat (e.g., the actual chemistry of an antihypertensive
drug versus the lowering of one's blood pressure). Longitudinal data
collected before the onset of symptoms would be needed to assess the
validity of this hypothesis. Second, it is possible that the interactions of
the drugs were responsible for the results given that 49% of the sample
was taking a combination of drugs. Although the sample size in this study
was too small to provide sufficient power to test hypotheses related to
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drug interactions, it should be noted that entering the total number of
drugs as a covariate did not change the results of the medication category
analyses in any meaningful way. Relatedly. this study focused on only
three categories of prescriptions. However, these three categories were
the most commonly reported in the study sample and other categories
were not adequately represented for statistical analyses. It is also possible
that drug usage served as a proxy for other protective or risk factors such as
access to health care or change in health behaviors following a diagnosis of
an illness or disorder. Finally, although the focus of this study was use of
prescription medication, over-the-counter (OTC) drugs may also influence
cognitive performance. Future research should include an in-depth investi-
gation of the influence of all types of medications, including OTC drugs.
A further consideration is the generalizability of the sample. As this
sample was relatively healthy and community dwelling, the results add
more information regarding noninstitutionalized, well older adults to the
existing literature. However, a number of other factors related to cogni-
tive performance, such as depression, anxiety, and presence of certain
chronic illnesses, were not assessed. In addition, this sample did not
include any minorities, which decreases the generalizability to additional
populations.
In terms of future investigations, this research could continue in several
directions. First is the comprehensive examination of the effects of
change in medication usage, which may include either how the change in
the number of prescriptions within each class is related to cognitive
performance over time, or the trajectory of medication effects (e.g.. Are
cognitive effects strongest when the person begins taking a medication?).
Relatedly, it may be of value to examine the issue of how actual adher-
ence to prescriptions influences cognitive performance. Dosing issues
(e.g.. prescribed dose, patient adherence) likely play an important role.
A second line of future research is the examination of the effects of
specific medication subtypes within each major category. For example,
this would entail looking at specific types of cardiovascular medications
(e.g., antihypertensives). These types of fine-grained analyses necessitate
a larger and more varied sample than what was analyzed in this study.
Although not a primary focus of the current study, it is interesting to
note that prescription medications played a role in explaining change in
cognitive performance above the influence of training condition. More
research is needed to examine the impact of prescription usage on cognitive
interventions aimed at older adults. For example, cognitive interventions
may serve to increase medication adherence as well as accuracy of medi-
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cation usage (e.g., dosage, timing). Future research might examine how
these effects play out differently over the course of an intervention protocol.
CONCLUSIONS
The results of this study have several implications that bridge basic and
applied geriatric practice. First, clinicians should consider medication
usage when making clinical and/or cognitive diagnoses due to the demon-
strated association between prescription medications and cognitive per-
formance (both basic and more everyday abilities). Second, long-term
care providers should be aware of the various effects of prescription
medications on different levels of cognitive performance and be obser-
vant of any changes in the behavior of older adult patients. Third, clinical
psychologists and therapists must be careful when introducing a treatment
that may be cognitively demanding with older adults due to possible cog-
nitive impairment related to medication use. Finally, researchers need to
account for medication usage (both number and type) when assessing
cognitive performance in older adults. This is particularly true for older
adults who are taking a number of medications or those who have added
or dropped prescriptions during the course of a study.
Overall, the results of this study support the use of specific cognitive
measures in the examination of the potential effects of prescription drugs
on both basic and higher-level cognitive performance, as well as the
continued study of the varying effects of drug class (e.g., cardiovascular,
central nervous system agents, and hormones) on cognition for men and
women. Furthermore, because the existing literature is equivocal in its
fmdings regarding the cognitive effects of prescription drugs, the results
of this study suggest that the use of more specific measures of cognitive
performance and category-specific measures of medications might better
elucidate the relation between prescription drugs and cognition.
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